RIGL Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 35.57%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 14.29%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 54.58%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.5%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.04x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.83x versus 4.95x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 10.24%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 14.29%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.90 which suggests that it could grow by 62.08%. Given that Amicus Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.04x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.83x versus 5.02x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 31.72%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Eli Lilly & Co.'s return on equity of 106.26%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 14.29%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,063.89 which suggests that it could grow by 6.65%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.50 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.04x while Eli Lilly & Co.'s PE ratio is 49.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.83x versus 15.31x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -301.29%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Nektar Therapeutics's return on equity of -327.67%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $49.60, signalling upside risk potential of 14.29%. On the other hand Nektar Therapeutics has an analysts' consensus of $107.29 which suggests that it could grow by 87.3%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.026% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.04x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.83x versus 60.61x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.